Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV- Negative Women
Sponsor: Centre for Infectious Disease Research in Zambia
Summary
A double blinded, Randomized, Placebo- controlled phase II trial to assess extended safety and tolerability of subcutaneous CAP256V2LS and VRC07-523LS in HIV- negative women
Official title: A Double-blinded, Randomized, Placebo-controlled Phase II Trial to Assess Extended Safety and Tolerability of Subcutaneous CAP256V2LS and VRC07-523LS in HIV Negative Women
Key Details
Gender
FEMALE
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
990
Start Date
2023-08-28
Completion Date
2025-06-30
Last Updated
2026-09-09
Healthy Volunteers
Yes
Interventions
Broad band monoclonal antibodies named as CAP256V2LS and VRC07- 523LS
HIV prevention
Locations (1)
Matero Clinical Research Site
Lusaka, Lusaka Province, Zambia